Riskpilot← Back to searchSign inGet full accessCoegin Pharma AB
ABActiveOrg 5590780465Scheeletorget 1Business and other management consultancy activities · NACE 7020Est. 20161 employees
Revenue 2024
SEK 570K
-55% vs 2023
EBITDA margin
-3303.0%
0% vs 2023
Equity ratio
98.1%
Financial strength
Net profit 2024
SEK -25,4M
+73% vs 2023
| Revenue | SEK 570K | -55% |
| EBITDA | SEK -18,8M | +0% |
| Net profit | SEK -25,4M | +73% |
| Total assets | SEK 86,4M | +15% |
| Equity | SEK 84,8M | +25% |
| Employees | 1 | — |
Legal name
Coegin Pharma AB
Org number
5590780465
Legal form
Aktiebolag
NACE code
7020 · Business and other management consultancy activities
Founded
28 september 2016
Share capital
SEK 12 439 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva forskning och utveckling av läkemedel, diagnostiska metoder för behandling av cancer och inflammatoriska sjukdomar och kommersialisering härav samt därmed förenlig verksamhet. Bolaget skall även tillhandahålla konsult- och managementtjänster inom läkemedelsutveckling. Vidare ska bolaget kunna äga och förvalta fast och lös egendom samt all därtill förenlig verksamhet.
Address
Scheeletorget 1
Email
je@coeginpharma.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 29 630 | 574 | 260 | 1 222 | 1 351 | 1 268 | 570 |
| Staff expenses | — | — | — | — | — | — | — | — |
| EBITDA | 0 | −14 469 | −13 774 | −2 995 | −7 826 | −15 069 | −18 837 | −18 827 |
| Depreciation & amort. | — | — | −0 | −0 | −0 | −2 677 | −2 871 | −2 871 |
| EBIT | 0 | −14 469 | −13 774 | −2 995 | −7 826 | −17 746 | −21 708 | −21 698 |
| Net financials | — | −346 | −12 895 | −117 | 35 | −1 141 | −72 626 | −3 737 |
| Profit before tax | 0 | −14 815 | −26 669 | −3 112 | −7 791 | −18 176 | −94 334 | −25 435 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | 0 | −14 815 | −26 669 | −3 112 | −7 791 | −18 176 | −94 334 | −25 435 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 0 | 22 428 | 25 209 | 109 402 | 132 086 | 155 181 | 75 111 | 86 435 |
| Equity | 0 | 12 272 | 24 247 | 108 883 | 130 437 | 148 404 | 67 825 | 84 756 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 10 155 | 963 | 519 | 1 649 | 6 777 | 7 286 | 1 679 |
| Total debt | — | 10 155 | 963 | 519 | 1 649 | 6 777 | 7 286 | 1 679 |
EBITDA margin
-3303.0%
This company
15.8%
Market median
-21005% vs market
20172024
Equity ratio
98.1%
This company
38.2%
Market median
+157% vs market
20172024
Return on equity
-30.0%
This company
18.4%
Market median
-263% vs market
20172024
Net profit margin
-4462.3%
This company
8.1%
Market median
-55190% vs market
20172024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20172024
Debt / equity
0.02×
This company
0.62×
Market median
+97% vs market
20172024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2016-09-01 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
TD Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
BM Chief Auditor | Chief Auditor | 2020 | — | — |
JC Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
FR Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
AO Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Chairman | 2023 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Coegin Pharma AB (this company)
Coegin Pharma ASReccura Therapeutics ASAvexxin Oncology ASRECCURA THERAPEUTICS ASAVEXXIN ONCOLOGY ASBoard members of Coegin Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tore Duvold | Chief Executive Officer | 0 companies |
| Bengt Michael Olsson | Chief Auditor | 0 companies |
| Jens Christer Eriksson | Chief Executive Officer | 0 companies |
| Fridtjov Rune Löderup | Chief Executive Officer | 0 companies |
| Anders Ola Bjärehäll | Chief Auditor | 0 companies |
| Staffan Lindgren | Board of Directors | 0 companies |
| Erlend Petter Skagseth | Board of Directors | 0 companies |
| Thoas Michael Fioretos | Board of Directors | 0 companies |
| Jesper Ramskov Jensen | Board of Directors | 0 companies |
| Harmen Gregor Jacobus Maria Brenninkemeijer | Chairman | 0 companies |
| Eva Ulrika Saers | Chairman | 0 companies |